Based on a randomized, open-label, phase II clinical study conducted by our center to evaluate the efficacy and safety of trastuzumab combined with anthracycline or non-anthracycline-platinum as neoadjuvant therapy for HER-2-positive breast cancer (NCT 02510781), this study prospectively and dynamically collected blood samples from the enrolled patients. This evidence concerns the gene ERBB2 and breast cancer.